SEC 13F Intelligence

Aquilo Capital Management, LLC / SLN

Aquilo Capital Management, LLC’s Silence Therapeutics PLC Position

Does Aquilo Capital Management, LLC own Silence Therapeutics PLC (SLN)? Not currently — the last reported position was 367.2K shares worth $3M in Q4 2024; the fund’s latest 13F (Q3 2025) no longer reports it.

Position Value
$3M
Q4 2024
Shares
367.2K
% of Portfolio
+3.81%
Quarters Held
10
position exited

Position History SLN

Reported value by quarter
Q3 ’22: $13MQ3 ’22Q4 ’22: $20MQ1 ’23: $8MQ1 ’23Q2 ’23: $7MQ3 ’23: $13MQ3 ’23Q4 ’23: $18MQ1 ’24: $12MQ1 ’24Q2 ’24: $10MQ3 ’24: $6MQ3 ’24Q4 ’24: $3Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q4 2024367.2K$3M+3.81%
Q3 2024317.2K$6M+4.37%
Q2 2024500.2K$10M+9.16%
Q1 2024574.2K$12M+9.30%
Q4 20231.04M$18M+11.29%
Q3 20231.31M$13M+11.68%
Q2 20231.31M$7M+4.00%
Q1 20231.31M$8M+3.37%
Q4 20221.28M$20M+7.36%
Q3 20221.26M$13M+4.57%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Aquilo Capital Management, LLC’s full portfolio or all institutional holders of SLN.